These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 9207435

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A.
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
    Peters WP, Rosner G, Ross M, Vredenburgh J, Meisenberg B, Gilbert C, Kurtzberg J.
    Blood; 1993 Apr 01; 81(7):1709-19. PubMed ID: 7681699
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization.
    Lemoli RM, de Vivo A, Damiani D, Isidori A, Tani M, Bonini A, Cellini C, Curti A, Gugliotta L, Visani G, Fanin R, Baccarani M.
    Blood; 2003 Sep 01; 102(5):1595-600. PubMed ID: 12714501
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
    Schmitz N, Dreger P, Zander AR, Ehninger G, Wandt H, Fauser AA, Kolb HJ, Zumsprekel A, Martin A, Hecht T.
    Bone Marrow Transplant; 1995 Feb 01; 15(2):261-6. PubMed ID: 7539668
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, Berkman E, Schenkein D.
    Bone Marrow Transplant; 1999 Sep 01; 24(5):473-81. PubMed ID: 10482930
    [Abstract] [Full Text] [Related]

  • 15. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
    Cioch M, Jawniak D, Kotwica K, Wach M, Mańko J, Gorący A, Klimek P, Mazurkiewicz E, Jarosz P, Hus M.
    Transplant Proc; 2014 Oct 01; 46(8):2882-4. PubMed ID: 25380941
    [Abstract] [Full Text] [Related]

  • 16. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S, Karakus E, Kaynar L, Kurnaz F, Pala C, Keklik M, Zararsiz G, Solmaz M, Eser B, Cetin M, Unal A.
    Transfus Apher Sci; 2013 Jun 01; 48(3):315-20. PubMed ID: 23611684
    [Abstract] [Full Text] [Related]

  • 17. Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients.
    Gyger M, Sahovic E, Aslam M.
    Blood; 1998 Nov 01; 92(9):3489-90. PubMed ID: 9787199
    [No Abstract] [Full Text] [Related]

  • 18. Hemopoietic stem-cell harvesting and transplantation using G-CSF-primed BM: comparison with unprimed BM and G-CSF-primed PBSC.
    Lowenthal RM, Tuck D, Tegg E, Marsden KA, Rees B, Luck J, Ragg S, Parker N, Kotlovsky N.
    Cytotherapy; 1999 Nov 01; 1(5):409-16. PubMed ID: 20426541
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
    Hassan HT, Stockschläder M, Schleimer B, Krüger W, Zander AR.
    Transpl Immunol; 1996 Dec 01; 4(4):319-23. PubMed ID: 8972563
    [Abstract] [Full Text] [Related]

  • 20. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
    Bolwell BJ, Fishleder A, Andresen SW, Lichtin AE, Koo A, Yanssens T, Burwell R, Baucco P, Green R.
    Bone Marrow Transplant; 1993 Dec 01; 12(6):609-14. PubMed ID: 7511016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.